Obinutuzumab vs Rituximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Lymphocytic Leukemia
Shared mechanism: CD20 · full Chronic Lymphocytic Leukemia pipeline
Obinutuzumab
Marketed by Roche and partners
NCT01010061 · Phase 3 · completed
Patients were randomly assigned to obinutuzumab plus chlorambucil or chlorambucil alone, but the study was open-label rather than double-blinded. The primary clinical endpoint, progression-free survival, was met, with 31.1 versus 11.1 months and p<0.0001; the substantial randomized sample supports reliable evidence, while the lack of blinding limits the overall strength rating.
Next expected readout: November 2026 · NCT04895436 (registry estimate)
No aligned efficacy figure on record for this race.
Rituximab · Rituxan
Marketed by Roche and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT03467867 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Lymphocytic Leukemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Obinutuzumab: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.
Rituximab: registry results are on file for Chronic Lymphocytic Leukemia, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Obinutuzumab's landscape · Rituximab's landscape